Pharming is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Pharming’s lead product, RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (“HAE”) attacks in patients in Europe, the US, Israel, and South Korea.

Biotechnology

Pharming Group

Sijmen de Vries

Daniela dos Anjos Hanova

Alexander Breidenbach

Anurag Relan

Mireille Sanders

Stephen Toor

Jeroen Wakkerman

Ruud van Outersterp

Medical and Scientific Affairs

Market Access and Business Operations

Leadership Team

Compliance and Regulatory Affairs

Finance Team

Teams at Pharming Group

Medical and Scientific Affairs

Market Access and Business Operations

Leadership Team

Compliance and Regulatory Affairs

Finance Team